{
    "clinical_study": {
        "@rank": "45227", 
        "arm_group": [
            {
                "arm_group_label": "Guanfacine 3 mg/day IR", 
                "arm_group_type": "Experimental", 
                "description": "Guanfacine 3 mg/day immediate release"
            }, 
            {
                "arm_group_label": "Guanfacine 4mg/day ER", 
                "arm_group_type": "Experimental", 
                "description": "Guanfacine 4mg/day extended release"
            }, 
            {
                "arm_group_label": "Guanfacine 6mg/day ER", 
                "arm_group_type": "Experimental", 
                "description": "Guanfacine 6 mg/day extended release"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces\n      pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine."
        }, 
        "brief_title": "PK/PD Comparison of Guanfacine ER and IR", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65\n\n          -  Able to read, write and comprehend English\n\n          -  Smoker\n\n          -  Able to take oral medications and willing to adhere to medication regimen\n\n          -  Provide evidence of a stable living residence in the last 2 months, have reasonable\n             transportation to the study site, and have no plans to move within the next 3 months\n             or unresolved legal problems.\n\n        Exclusion Criteria:\n\n          -  Any significant current medical conditions that would contraindicate smoking\n\n          -  Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or\n             dependence of other substances, other than nicotine dependence or alcohol abuse\n\n          -  Positive test results at intake appointment on urine drug screens for illicit drugs\n\n          -  Past 30 day use of psychoactive drugs including anxiolytics and antidepressants\n\n          -  Women who are pregnant or nursing\n\n          -  Suicidal, homicidal or evidence of current mental illness such as schizophrenia,\n             bipolar disorder or major depression, or anxiety disorders\n\n          -  Meeting DSM-IV criteria for current attention deficit hyperactivity disorder (ADHD)\n\n          -  Individuals who are currently taking medications known to be effective for smoking\n             cessation or are regular users of other tobacco products in the past 30 days\n\n          -  Only one member per household can participate in the study\n\n          -  Specific exclusions for administration of guanfacine not already specified include:\n\n               -  EKG evidence at baseline screening of any clinically significant conduction\n                  abnormalities or arrhythmias\n\n               -  Known intolerance for guanfacine or any alpha blocker\n\n               -  History of fainting, syncopal attacks\n\n               -  Heart failure or myocardial infarction\n\n               -  Impaired liver (as indicated by aspartate aminotransferase (AST), alanine\n                  aminotransferase (ALT) >3x normal)\n\n               -  Renal function (as indicated by estimated creatinine clearance <60cc/min)\n\n               -  Treatment with any antihypertensive drug or any alpha-adrenergic blocker\n\n               -  Use of any central nervous system depressant (e.g., phenothiazines,\n                  barbiturates, benzodiazepines)\n\n               -  Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole) or\n                  inducers (e.g., rifampin), or consumption of grapefruit juice\n\n          -  Subjects may have not donated blood in the past 8 weeks or have been involved in\n             other investigational studies that involve substantial blood draws or medications\n             unknown to us"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904526", 
            "org_study_id": "1110009133", 
            "secondary_id": "R01DA035001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Guanfacine 3 mg/day IR", 
                "Guanfacine 4mg/day ER", 
                "Guanfacine 6mg/day ER"
            ], 
            "description": "3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.", 
            "intervention_name": "Guanfacine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Tenex", 
                "Intuniv"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Guanfacine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Guanfacine", 
            "PK/PD", 
            "Smokers"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Yale Center for Clinical Investigations, Yale University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Pharmacokinetic/Dynamic (PK/PD) Comparison of Guanfacine Extended Release (ER) and Immediate Release (IR) in Smokers", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Sherry A McKee, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Plasma trough levels of guanfacine", 
            "measure": "Evaluate whether a 4mg/day or 6mg/day dose of extended-release guanfacine produces PK properties similar to 3mg/day immediate release guanfacine.", 
            "safety_issue": "No", 
            "time_frame": "Lab Sessions (Days 22, 49, 58)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904526"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Sherry McKee", 
            "investigator_title": "Associate Professor of Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Heart rate and Blood Pressure throughout the study", 
            "measure": "Evaluate the safety and tolerability of guanfacine", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 of titration 1 to the end of followup following the 3rd lab session, which on average will be 2 months."
        }, 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}